We found that some of the same pathways are present in cancers(Fig. 5a), which includes PID CD8 TCR Downstream Pathway in BLCA, BRCA, ESAD, ESCA, GBM, KIRP, LIHC, LUSC, OV, PRAD, SKCM, STAD, UCS, UVM; PID CD8 TCR Pathway in BLCA, BRCA, ESCA, GBM, LIHC, LUSC, OV, PRAD, SKCM, STAD, TGCT, UCS, UVM; WP T cell Antigen Receptor TCR Signal Pathway in BLCA, BRCA, ESCA, GBM, KIRP, LIHC, LUSC, OV, PRAD, SKCM, STAD, TGCT, UCS, UVM; BIOCARTA CTLA4 Pathway and WP Cancer Immunotherapy By PD1 Blockade in BLCA, BRCA, ESCA, LIHC, LUSC, OV, PRAD, SKCM, STAD, TGCT, UCS, UVM. This evidence concerns the gene MTA2 and bladder transitional cell carcinoma.